The gold standard treatment for typical AMD is the intravitreal injection consisting of anti-vascular endothelial growth factor (VEGF) agents, such as aflibercept and ranibizumab, because the treatment resolves CNV-related exudates and improves or maintains visual acuity in most patients with AMD [2–4]. Here, VEGFA is linked to age-related macular degeneration.